Scientific Reports (Apr 2021)

A multiparametric extraction method for Vn96-isolated plasma extracellular vesicles and cell-free DNA that enables multi-omic profiling

  • Jeremy W. Roy,
  • Catherine A. Taylor,
  • Annie P. Beauregard,
  • Surendar R. Dhadi,
  • D. Craig Ayre,
  • Sheena Fry,
  • Simi Chacko,
  • Gabriel Wajnberg,
  • Andrew P. Joy,
  • Ngoc-Nu Mai-Thi,
  • Nicolas Crapoulet,
  • David A. Barnett,
  • Anirban Ghosh,
  • Stephen M. Lewis,
  • Rodney J. Ouellette

DOI
https://doi.org/10.1038/s41598-021-87526-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Extracellular vesicles (EVs) have been recognized as a rich material for the analysis of DNA, RNA, and protein biomarkers. A remaining challenge for the deployment of EV-based diagnostic and prognostic assays in liquid biopsy testing is the development of an EV isolation method that is amenable to a clinical diagnostic lab setting and is compatible with multiple types of biomarker analyses. We have previously designed a synthetic peptide, known as Vn96 (ME kit), which efficiently isolates EVs from multiple biofluids in a short timeframe without the use of specialized lab equipment. Moreover, it has recently been shown that Vn96 also facilitates the co-isolation of cell-free DNA (cfDNA) along with EVs. Herein we describe an optimized method for Vn96 affinity-based EV and cfDNA isolation from plasma samples and have developed a multiparametric extraction protocol for the sequential isolation of DNA, RNA, and protein from the same plasma EV and cfDNA sample. We are able to isolate sufficient material by the multiparametric extraction protocol for use in downstream analyses, including ddPCR (DNA) and ‘omic profiling by both small RNA sequencing (RNA) and mass spectrometry (protein), from a minimum volume (4 mL) of plasma. This multiparametric extraction protocol should improve the ability to analyse multiple biomarker materials (DNA, RNA and protein) from the same limited starting material, which may improve the sensitivity and specificity of liquid biopsy tests that exploit EV-based and cfDNA biomarkers for disease detection and monitoring.